Sphera Funds Management Ltd. Argenx Se Transaction History

Sphera Funds Management Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $553,951 - $702,611	1,556 New	1,556 $669,000
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $1.09 Million - $1.51 Million	-4,291 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$272.01 - $353.03 $1.35 Million - $1.75 Million	-4,958 Reduced 53.61%	4,291 $1.5 Million
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $252,100 - $313,293	-1,016 Reduced 9.9%	9,249 $2.72 Million
Q1 2020 May 14, 2020	SELL	$108.83 - $165.23 $687,370 - $1.04 Million	-6,316 Reduced 38.09%	10,265 $1.35 Million
Q4 2019 Feb 13, 2020	SELL	$106.59 - $164.21 $2.34 Million - $3.61 Million	-22,000 Reduced 57.02%	16,581 $2.66 Million
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $575,000 - $707,900	5,000 Added 14.89%	38,581 $0
Q1 2019 May 15, 2019	SELL	$98.85 - $134.59 $5.29 Million - $7.2 Million	-53,500 Reduced 61.44%	33,581 $4.19 Million
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $3.15 Million - $5.41 Million	-49,300 Reduced 36.15%	87,081 $8.37 Million
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $10.3 Million - $13.2 Million	136,381 New	136,381 $10.3 Million

428

29.2M

389K

270K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $35.4B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.